Formulation Development

We believe that topical JAK inhibitor therapy for alopecia areata requires the drug to be delivered to the site of the inflammation, deep in the skin at the base (bulb) of the hair follicle. ARQ-255 is an alternative topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata.  We currently have formulation and preclinical efforts underway, and if these are successful, we plan to enter the clinic with ARQ-255 as a potential treatment for alopecia areata.